Mortality in SLE

Dubois' Lupus Erythematosus and Related Syndromes: Eighth Edition

Volumn , Issue , 2013, Pages 666-675

  Bernatsky, Sasha ^a   Levy, Deborah ^b   Ramsey Goldman, Rosalind ^c   Gordon, Caroline ^d   Rahman, Anisur ^e   Clarke, Ann E ^f  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942885058     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1893-5.00057-1     Document Type: Chapter

References (98)

1. Merrell M, Shulman Le Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1955, 1(1):12-32.
2. Borchers AT, Keen CL, Shoenfeld Y, et al. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004, 3(6):423-453.
3. Trager J, Ward MM Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001, 13(5):345-351.
4. Uramoto KM, Michet CJ, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999, 42(1):46-50.
5. Therneau TM, Offord J Expected survival based on hazard rates (updated) 63:1-26, 1999. Rochester, MN, Mayo Clinic-Section of Biostatistics. Available at. http://mayoresearch.mayo.edu/mayo/research/biostat/upload/63.pdf.
6. Seleznick MJ, Fries JF Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 1991, 21(2):73-80.
7. Kaslow RA, Masi AT Age, sex, and race effects on mortality from systemic lupus erythematosus in the United States. Arthritis Rheum 1978, 21(4):473-479.
8. Reveille JD, Bartolucci A, Alarcón GS Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990, 33(1):37-48.
9. Alarcón GS, McGwin G, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA study group. Arthritis Rheum 2001, 45(2):191-202.
10. Borchers AT, Naguwa SM, Shoenfeld Y, et al. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010, 9(5):A277-A287.
11. Walsh SJ, Algert C, Gregorio DI, et al. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol 1995, 22(9):1663-1668.
12. Calvo-Alén J, Alarcón GS, Campbell R, et al. Lack of recording of systemic lupus erythematosus in the death certificates of lupus patients. Rheumatology (Oxford) 2005, 44(9):1186-1189.
13. Korbet SM, Schwartz MM, Evans J, et al. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007, 18(1):244-254.
14. Fang J, Madhavan S, Cohen H, et al. Differential mortality in New York City (1988-1992). Part one: Excess mortality among non-Hispanic blacks. Bull N Y Acad Med 1995, 72(2):470-482.
15. Caetano R Alcohol-related health disparities and treatment-related epidemiological findings among whites, blacks, and Hispanics in the United States. Alcohol Clin Exp Res 2003, 27(8):1337-1339.
16. Kumar K, Chambers S, Gordon C Challenges of ethnicity in SLE. Best Pract Res Clin Rheumatol 2009, 23(4):549-561.
17. [No authors listed] A statistical profile on the health of First Nations in Canada: determinants of health, 1999 to 2003. Cat.: H34-193/1-2008, 1-62. 2009. Canada, Minister of Health Canada. Available at. http://www.hc-sc.gc.ca/fniah-spnia/alt_formats/fnihb-dgspni/pdf/pubs/aborig-autoch/2009-stats-profil-eng.pdf.
18. Urowitz MB, Gladman DD, Tom BD, et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008, 35(11):2152-2158.
19. Bernatsky S, Boivin J, Manzi S, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54(8):2550-2557.
20. Ippolito A, Petri M An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol 2008, 26(5 Suppl 51):S72-S79.
21. Estes D, Christian CL The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 1971, 50(2):85-95.
22. Mok CC, To CH, Ho LY, et al. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. J Rheumatol 2008, 35(10):1978-1982.
23. Mok CC, Kwok CL, Ho LY, et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum 2011, 63(5):1182-1189.
24. Urowitz MB, Gladman D, Ibanez D, et al. Mortality in a multinational inception cohort of SLE [Abstract]. Arthritis Rheum 2011, Suppl:S2240.
25. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145(5):408-415.
26. Björnådal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004, 31(4):713-719.
27. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349(25):2399-2406.
28. Dubois EL Systemic lupus erythematosus: recent advances in its diagnosis and treatment. Ann Intern Med 1956, 45(2):163-184.
29. Abu-Shakra M, Urowitz MB, Gladman DD, et al. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995, 22(7):1259-1264.
30. Bernatsky S, Clarke A, Gladman DD, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus 2006, 15(12):835-839.
31. Urowitz MB, Gladman DD The SLICC inception cohort for atherosclerosis. Curr Rheumatol Rep 2008, 10(4):281-285.
32. Elie C, De RY, Jais J, et al. Appraising relative and excess mortality in population-based studies of chronic diseases such as end-stage renal disease. Clin Epidemiol 2011, 3:157-169.
33. Hersh AO, Trupin L, Yazdany J, et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010, 62(8):1152-1159.
34. Scalzi LV, Hollenbeak CS, Wang L Racial disparities in age at time of cardiovascular events and cardiovascular-related death in patients with systemic lupus erythematosus. Arthritis Rheum 2010, 62(9):2767-2775.
35. Feng PH, Lin SM, Yu CT, et al. Inadequate antimicrobial treatment for nosocomial infection is a mortality risk factor for systemic lupus erythematous patients admitted to intensive care unit. Am J Med Sci 2010, 340(1):64-68.
36. Ward MM Association between physician volume and in-hospital mortality in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52(6):1646-1654.
37. Ward MM Hospital experience and expected mortality in patients with systemic lupus erythematosus: a hospital level analysis. J Rheumatol 2000, 27(9):2146-2151.
38. Ward MM Hospital experience and mortality in patients with systemic lupus erythematosus. Arthritis Rheum 1999, 42(5):891-898.
39. Sule S, Fivush B, Neu A, et al. Increased risk of death in pediatric and adult patients with ESRD secondary to lupus. Pediatr Nephrol 2011, 26(1):93-98.
40. Danila MI, Pons-Estel GJ, Zhang J, et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009, 48(5):542-545.
41. Liang CC, Lin HH, Wang IK, et al. Influence of predialysis comorbidity and damage accrual on mortality in lupus patients treated with peritoneal dialysis. Lupus 2010, 19(10):1210-1218.
42. Sidhu MS, Dellsperger KC Cardiovascular problems in dialysis patients: impact on survival. Adv Perit Dial 2010, 26:47-52.
43. Foley RN, Parfrey PS, Harnett JD, et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996, 49(5):1379-1385.
44. Ward MM Education level and mortality in systemic lupus erythematosus (SLE): evidence of underascertainment of deaths due to SLE in ethnic minorities with low education levels. Arthritis Rheum 2004, 51(4):616-624.
45. Studenski S, Allen NB, Caldwell DS, et al. Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors. Arthritis Rheum 1987, 30(12):1326-1332.
46. Ward MM, Pyun E, Studenski S Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum 1995, 38(2):274-283.
47. Kasitanon N, Magder LS, Petri M Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006, 85(3):147-156.
48. Cook RJ, Gladman DD, Pericak D, et al. Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol 2000, 27(8):1892-1895.
49. Stoll T, Seifert B, Isenberg DA SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996, 35(3):248-254.
50. Croca SC, Rodrigues T, Isenberg DA Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011, 50(8):1424-1430.
51. Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002, 61(12):1065-1070.
52. Ward MM, Pajevic S, Dreyfuss J, et al. Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests. Arthritis Rheum 2006, 55(1):74-80.
53. Ward MM, Pyun E, Studenski S Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 1996, 156(12):1337-1344.
54. Hernández-Cruz B, Tapia N, Villa-Romero AR, et al. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. Clin Exp Rheumatol 2001, 19(4):395-401.
55. Zonana-Nacach A, Yanez P, Jiménez-Balderas FJ, et al. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus 2007, 16(12):997-1000.
56. Kamphuis S, Silverman ED Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010, 6(9):538-546.
57. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics.". Medicine (Baltimore) 2004, 83(1):1-17.
58. Tucker LB, Uribe AG, Fernandez M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 2008, 17(4):314-322.
59. Cook CD, Wedgwood RJ, Craig JM, et al. Systemic lupus erythematosus. Description of 37 cases in children and a discussion of endocrine therapy in 32 of the cases. Pediatrics 1960, 26:570-585.
60. Meislin AG, Rothfield N Systemic lupus erythematosus in childhood. Analysis of 42 cases, with comparative data on 200 adult cases followed concurrently. Pediatrics 1968, 42(1):37-49.
61. Walravens PA, Chase HP The prognosis of childhood systemic lupus erythematosus. Am J Dis Child 1976, 130(9):929-933.
62. Fish AJ, Blau EB, Westberg NG, et al. Systemic lupus erythematosus within the first two decades of life. Am J Med 1977, 62(1):99-117.
63. Abeles M, Urman JD, Weinstein A, et al. Systemic lupus-erythematosus in the younger patient: survival studies. J Rheumatol 1980, 7(4):515-522.
64. Caeiro F, Michielson FM, Bernstein R, et al. Systemic lupus erythematosus in childhood. Ann Rheum Dis 1981, 40(4):325-331.
65. Platt JL, Burke BA, Fish AJ, et al. Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis 1982, 2(1 Suppl 1):212-222.
66. Glidden RS, Mantzouranis EC, Borel Y Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients. Clin Immunol Immunopathol 1983, 29(2):196-210.
67. Hagelberg S, Lee Y, Bargman J, et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002, 29(12):2635-2642.
68. Miettunen PM, Ortiz-Alvarez O, Petty RE, et al. Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. J Rheumatol 2004, 31(8):1650-1654.
69. Hashkes PJ, Wright BM, Lauer MS, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 2010, 62(2):599-608.
70. Candell Chalom E, Periera B, Cole R, et al. Educational, vocational and socioeconomic status and quality of life in adults with childhood-onset systemic lupus erythematosus. Pediatr Rheumatol Online J 2004, 2:207-226.
71. Vachvanichsanong P, Dissaneewate P, McNeil E Twenty-two years' experience with childhood-onset SLE in a developing country: are outcomes similar to developed countries?. Arch Dis Child 2011, 96(1):44-49.
72. McCurdy DK, Lehman TJA, Bernstein B, et al. Lupus nephritis: prognostic factors in children. Pediatrics 1992, 89(2):240-246.
73. Baqi N, Moazami S, Singh A, et al. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 1996, 7(6):924-929.
74. Emre S, Bilge I, Sirin A, et al. Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron 2001, 87(2):118-126.
75. Bogdanović R, Nikolić V, Pasić S, et al. Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol 2004, 19(1):36-44.
76. Yang LY, Chen WP, Lin CY Lupus nephritis in children-a review of 167 patients. Pediatrics 1994, 94(3):335-340.
77. Lo JT, Tsai MJ, Wang LH, et al. Sex differences in pediatric systemic lupus erythematosus: a retrospective analysis of 135 cases. J Microbiol Immunol Infect 1999, 32(3):173-178.
78. Wang LC, Yang YH, Lu MY, et al. Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades. J Microbiol Immunol Infect 2003, 36(3):203-208.
79. Yu HH, Lee JH, Wang LC, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus 2006, 15(10):651-657.
80. Pattaragarn A, Sumboonnanonda A, Parichatikanond P, et al. Systemic lupus erythematosus in Thai children: clinicopathologic findings and outcome in 82 patients. J Med Assoc Thai 2005, 88(Suppl 8):S232-S241.
81. Wong SN, Tse KC, Lee TL, et al. Lupus nephritis in Chinese children-a territory-wide cohort study in Hong Kong. Pediatr Nephrol 2006, 21(8):1104-1112.
82. Lee BW, Yap HK, Yip WCL, et al. A 10 year review of systemic lupus-erythematosus in Singapore children. Aust Paediatr J 1987, 23(3):163-165.
83. Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr Nephrol 2007, 22(2):222-231.
84. González B, Hernández P, Olguin H, et al. Changes in the survival of patients with systemic lupus erythematosus in childhood: 30 years experience in Chile. Lupus 2005, 14(11):918-923.
85. Hiraki LT, Lu B, Alexander SR, et al. End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum 2011, 63(7):1988-1997.
86. Pineau CA, Bernatsky S, Abrahamowicz M, et al. A comparison of damage accrual across different calendar periods in systemic lupus erythematosus patients. Lupus 2006, 15(9):590-594.
87. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998, 7(2):80-85.
88. Millet A, Decaux O, Perlat A, et al. Systemic lupus erythematosus and vaccination. Eur J Intern Med 2009, 20(3):236-241.
89. Lu CC, Wang YC, Lai JH, et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine 2011, 29(3):444-450.
90. Ori E, Sharon A, Ella M, et al. The efficacy and safety of vaccination against pandemic 2009 influenza a (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011, 63(7):1062-1067.
91. Ward MM Hospital experience and mortality in patients with systemic lupus erythematosus: Which patients benefit most from treatment at highly experienced hospitals?. J Rheumatol 2002, 29(6):1198-1206.
92. Chambers S, Raine R, Rahman A, et al. Factors influencing adherence to medications in a group of patients with systemic lupus erythematosus in Jamaica. Lupus 2008, 17(8):761-769.
93. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2008, 27(7):883-889.
94. Chambers SA, Raine R, Rahman A, et al. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford) 2009, 48(3):266-271.
95. Koneru S, Kocharla L, Higgins GC, et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol 2008, 14(4):195-201.
96. Kumar K, Gordon C, Barry R, et al. "It's like taking poison to kill poison but I have to get better": a qualitative study of beliefs about medicines in rheumatoid arthritis and systemic lupus erythematosus patients of South Asian origin. Lupus 2011, 20(8):837-844.
97. Kumar K, Gordon C, Toescu V, et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology (Oxford) 2008, 47(5):690-697.
98. Demas KL, Costenbader KH Disparities in lupus care and outcomes. Curr Opin Rheumatol 2009, 21(2):102-109.